Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda Cà Granda | Fundación para la Investigación del Hospital Clínico de Valencia | University of Campania Luigi Vanvitell
Deal Size : Inapplicable
Deal Type : Inapplicable
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2018
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda Cà Granda | Fundación para la Investigación del Hospital Clínico de Valencia | University of Campania Luigi Vanvitell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2017
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Galunisertib in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2016
Lead Product(s) : Galunisertib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2016
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2016
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2015
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Galunisertib on the Immune System in Participants With Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2014
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2014
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2014
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2014
Lead Product(s) : Galunisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable